Details

No. of pages:
744
Language:
English
Copyright:
© 2011
Published:
Imprint:
Academic Press
Print ISBN:
9780123809261
Electronic ISBN:
9780123809278

About the author

Shlomo Melmed

Affiliations and Expertise

Professor of Medicine, Senior Vice President and Dean of the Medical Faculty, Cedars Sinai Health System, Los Angeles, California

Reviews

"…the book is not only a must for scientists and clinicians usually involved in the management of neuroendocrine dysfunctions but also a great opportunity for other specialists (internists, pediatricians, gynecologists, neurosurgeons) as well as for medical students to familiarize at best with the pituitary and its disorders. In all, this book is a traditional masterpiece dedicated to the ‘‘master gland’’ by one of the most important opinion leaders in the field."--Endocrine 2012 vol.41 p.159

"[T]he book provides the reader a unique opportunity to understand in depth the mechanisms subserving both normal and disordered pituitary hormone secretion and action. Thus, the book is not only a must for scientists and clinicians usually involved in the management of neuroendocrine dysfunctions but also a great opportunity for other specialists (internists, pediatricians, gynecologists, neurosurgeons) as well as for medical students to familiarize at best with the pituitary and its disorders. In all, this book is a traditional masterpiece dedicated to the ‘‘master gland’’ by one of the most important opinion leaders in the field."--Endocrine

SECOND EDITION:

"This excellent second edition is an update of the highly successful first edition of The Pituitary, published in 1995…All the chapters were written by leading experts in the field; a particularly welcome addition is a chapter dedicated to pituitary surgery, by Fahlbusch and colleagues. All the chapters have been successfully updated, and all are comprehensively referenced. The new edition describes recent developments in medical therapies for acromegaly (and thyrotropin-producing adenomas), especially the role of long-acting forms of somatostatin analogues and new growth hormone-receptor antagonists, as well as newer and more effective dopamine agonists for patients with prolactinoma. Inevitably, availability and licensing are subject to worldwide variations an